{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:19:18Z","timestamp":1778660358789,"version":"3.51.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T00:00:00Z","timestamp":1528156800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40259-018-0285-2","type":"journal-article","created":{"date-parts":[[2018,6,5]],"date-time":"2018-06-05T07:54:41Z","timestamp":1528185281000},"page":"377-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7810-6831","authenticated-orcid":false,"given":"Ariane G. S.","family":"Araujo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-584X","authenticated-orcid":false,"given":"Helena H. L.","family":"Borba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-8608","authenticated-orcid":false,"given":"Fernanda S.","family":"Tonin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-1703","authenticated-orcid":false,"given":"Luana","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-8503","authenticated-orcid":false,"given":"Rafael","family":"Venson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7049-4363","authenticated-orcid":false,"given":"Roberto","family":"Pontarolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-4044","authenticated-orcid":false,"given":"Astrid","family":"Wiens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,5]]},"reference":[{"issue":"6","key":"285_CR1","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis."},{"issue":"10055","key":"285_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023\u201338.","journal-title":"Lancet"},{"issue":"4","key":"285_CR3","doi-asserted-by":"publisher","first-page":"e0175099","DOI":"10.1371\/journal.pone.0175099","volume":"12","author":"H Patel","year":"2017","unstructured":"Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn\u2019s disease in the United States. PLoS One. 2017;12(4):e0175099.","journal-title":"PLoS One"},{"issue":"8","key":"285_CR4","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jid.2017.04.009","volume":"137","author":"ZK Jabbar-Lopez","year":"2017","unstructured":"Jabbar-Lopez ZK, et al. Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis. J Invest Dermatol. 2017;137(8):1646\u201354.","journal-title":"J Invest Dermatol"},{"key":"285_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12891-016-1102-z","volume":"17","author":"JB Palmer","year":"2016","unstructured":"Palmer JB, et al. Treatment patterns and costs for anti-TNFalpha biologic therapy in patients with psoriatic arthritis. BMC Musculoskelet Disord. 2016;17:261.","journal-title":"BMC Musculoskelet Disord"},{"key":"285_CR6","first-page":"Cd008794","volume":"2","author":"JA Singh","year":"2011","unstructured":"Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;2:Cd008794.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"285_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40744-017-0055-5","volume":"4","author":"LM Verhoef","year":"2017","unstructured":"Verhoef LM, et al. bDMARD dose reduction in rheumatoid arthritis: a narrative review with systematic literature search. Rheumatol Ther. 2017;4(1):1\u201324.","journal-title":"Rheumatol Ther."},{"issue":"11","key":"285_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2011.145","volume":"7","author":"RS Woodrick","year":"2011","unstructured":"Woodrick RS, Ruderman EM. Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol. 2011;7(11):639\u201352.","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"285_CR9","doi-asserted-by":"publisher","first-page":"865","DOI":"10.2165\/11538330-000000000-00000","volume":"33","author":"TJ Giezen","year":"2010","unstructured":"Giezen TJ, et al. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Drug Saf. 2010;33(10):865\u201378.","journal-title":"Drug Saf"},{"issue":"3","key":"285_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40264-013-0018-x","volume":"36","author":"PM Coloma","year":"2013","unstructured":"Coloma PM, et al. Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture? Drug Saf. 2013;36(3):183\u201397.","journal-title":"Drug Saf"},{"issue":"2","key":"285_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00002018-200932020-00003","volume":"32","author":"M Hauben","year":"2009","unstructured":"Hauben M, Aronson JK. Defining \u2018signal\u2019 and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf. 2009;32(2):99\u2013110.","journal-title":"Drug Saf"},{"issue":"5","key":"285_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1517\/14740338.4.5.929","volume":"4","author":"M Hauben","year":"2005","unstructured":"Hauben M, et al. The role of data mining in pharmacovigilance. Expert Opin Drug Saf. 2005;4(5):929\u201348.","journal-title":"Expert Opin Drug Saf"},{"key":"285_CR13","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. European Medicines Agency. Electronic transmission of individual case safety reports message specification (ICH ICSR DTD Version 2.1) 2001. \n                    http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/FormsSubmissionRequirements\/ElectronicSubmissions\/UCM149932.pdf\n                    \n                  . 06 Jun 2015."},{"key":"285_CR14","unstructured":"U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS): Latest quarterly data files. 2015. \n                    http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/ucm082193.htm\n                    \n                  . 10 Oct 2015."},{"key":"285_CR15","unstructured":"ClinicalTrials.gov. A service of the U.S. National Institutes of Health. 2016. \n                    https:\/\/clinicaltrials.gov\/\n                    \n                  . 20 Jan 2016."},{"key":"285_CR16","unstructured":"DrugBank. Drug & drug target database. 2016. \n                    http:\/\/www.drugbank.ca\/\n                    \n                  . 20 Jan 2016."},{"key":"285_CR17","unstructured":"Drugs.com. Drug index a to z. 2016. \n                    http:\/\/www.drugs.com\/\n                    \n                  . 15 Jan 2016."},{"key":"285_CR18","unstructured":"European Medicines Agency. European public assessment reports. 2016. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/landing\/epar_search.jsp&mid=WC0b01ac058001d124\n                    \n                  . 30 Sept 2016."},{"key":"285_CR19","unstructured":"U.S Food and Drug Administration. Drugs@FDA. 2016. \n                    http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm\n                    \n                  . 20 Jan 2016."},{"key":"285_CR20","unstructured":"GenericDrugs. Therapeutic equivalent brand and generic drugs. 2016. \n                    http:\/\/www.ndrugs.com\/\n                    \n                  . 20 Jan 2016."},{"issue":"1","key":"285_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"285_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","volume":"75","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3\u201315.","journal-title":"Ann Rheum Dis."},{"issue":"7","key":"285_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/pds.3805","volume":"24","author":"CK Wong","year":"2015","unstructured":"Wong CK, et al. Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants. Pharmacoepidemiol Drug Saf. 2015;24(7):731\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"285_CR24","unstructured":"International Organization for Standardization-Country Codes-ISO 3166. 2015. \n                    http:\/\/www.iso.org\/iso\/home\/standards\/country_codes.htm\n                    \n                  . 15 Nov 2015."},{"key":"285_CR25","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Medical dictionary for regulatory activities (MedDRA). 2016. \n                    http:\/\/www.ich.org\/products\/meddra.html\n                    \n                  . 15 Sept 2016."},{"issue":"3","key":"285_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00228-012-1387-2","volume":"69","author":"RE Hubbard","year":"2013","unstructured":"Hubbard RE, O\u2019Mahony MS, Woodhouse KW. Medication prescribing in frail older people. Eur J Clin Pharmacol. 2013;69(3):319\u201326.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"285_CR27","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/003693309704200506","volume":"42","author":"G Cunningham","year":"1997","unstructured":"Cunningham G. Adverse drug reactions in the elderly and their prevention. Scott Med J. 1997;42(5):136\u20137.","journal-title":"Scott Med J"},{"issue":"11","key":"285_CR28","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40264-014-0224-1","volume":"37","author":"PM Cutroneo","year":"2014","unstructured":"Cutroneo PM, et al. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database. Drug Saf. 2014;37(11):961\u201370.","journal-title":"Drug Saf"},{"issue":"1","key":"285_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.reuma.2012.04.007","volume":"9","author":"MV Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez MV, Meineri M, Sanmart\u00ed R. Lesiones cut\u00e1neas y terapia biol\u00f3gica con antagonistas del factor de necrosis tumoral. Reumatolog\u00eda Cl\u00ednica. 2013;9(1):53\u201361.","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"issue":"6","key":"285_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AF Wisniewski","year":"2016","unstructured":"Wisniewski AF, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39(6):469\u201390.","journal-title":"Drug Saf"},{"issue":"4","key":"285_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40264-015-0388-3","volume":"39","author":"S Seabroke","year":"2016","unstructured":"Seabroke S, et al. Performance of stratified and subgrouped disproportionality analyses in spontaneous databases. Drug Saf. 2016;39(4):355\u201364.","journal-title":"Drug Saf"},{"issue":"1","key":"285_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP Puijenbroek van","year":"2002","unstructured":"van Puijenbroek EP, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"285_CR33","unstructured":"European Medicines Agency. Designated Medical Event (DME) list. 2016. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/general\/general_content_000587.jsp&mid=WC0b01ac0580727d1b\n                    \n                  . 15 Oct 2016."},{"key":"285_CR34","unstructured":"European Medicines Agency. 19.1 IME list. 2016. \n                    http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/regulation\/q_and_a\/q_and_a_detail_000166.jsp&mid=WC0b01ac0580a68f78\n                    \n                  . Accessed 2 June 2018."},{"issue":"3","key":"285_CR35","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jcpt.12148","volume":"39","author":"D Mendes","year":"2014","unstructured":"Mendes D, Alves C, Batel-Marques F. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. J Clin Pharm Ther. 2014;39(3):307\u201313.","journal-title":"J Clin Pharm Ther"},{"issue":"12","key":"285_CR36","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2165\/11318980-000000000-00000","volume":"32","author":"TJ Giezen","year":"2009","unstructured":"Giezen TJ, et al. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. Drug Saf. 2009;32(12):1175\u201387.","journal-title":"Drug Saf"},{"key":"285_CR37","first-page":"265","volume-title":"Data mining applications in engineering and medicine","author":"E Poluzzi","year":"2012","unstructured":"Poluzzi E, et al. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: Karahoca, editor. Data mining applications in engineering and medicine. Croatia: InTech; 2012. p. 265\u2013302."},{"key":"285_CR38","first-page":"1","volume":"9","author":"C Codreanu","year":"2015","unstructured":"Codreanu C, Damjanov N. Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biol Targets Ther. 2015;9:1\u20136.","journal-title":"Biol Targets Ther"},{"issue":"1","key":"285_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1517\/17460440903443410","volume":"5","author":"R Dixit","year":"2010","unstructured":"Dixit R, et al. Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal models. Expert Opin Drug Discov. 2010;5(1):79\u201394.","journal-title":"Expert Opin Drug Discov"},{"issue":"10","key":"285_CR40","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2165\/11316550-000000000-00000","volume":"32","author":"TJ Giezen","year":"2009","unstructured":"Giezen TJ, Mantel-Teeuwisse AK, Leufkens HG. Pharmacovigilance of biopharmaceuticals: challenges remain. Drug Saf. 2009;32(10):811\u20137.","journal-title":"Drug Saf"},{"issue":"16","key":"285_CR41","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1001\/jama.300.16.1887","volume":"300","author":"TJ Giezen","year":"2008","unstructured":"Giezen TJ, et al. Safety-related regulatory actions for biologicals approved in the United States and the European Union. Jama. 2008;300(16):1887\u201396.","journal-title":"Jama"},{"key":"285_CR42","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.rbr.2014.06.006","volume":"55","author":"LMHD Mota","year":"2015","unstructured":"Mota LMHD, et al. Seguran\u00e7a do uso de terapias biol\u00f3gicas para o tratamento de artrite reumatoide e espondiloartrites. Revista Brasileira de Reumatologia. 2015;55:281\u2013309.","journal-title":"Revista Brasileira de Reumatologia"},{"issue":"1","key":"285_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.jidsymp.5650029","volume":"12","author":"AB Gottlieb","year":"2007","unstructured":"Gottlieb AB. Tumor necrosis factor blockade: mechanism of action. J Investig Dermatol Symp Proc. 2007;12(1):1\u20134.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"6","key":"285_CR44","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2217\/imt.10.67","volume":"2","author":"LC Silva","year":"2010","unstructured":"Silva LC, Ortigosa LC, Benard G. Anti-TNF-alpha agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy. 2010;2(6):817\u201333.","journal-title":"Immunotherapy"},{"key":"285_CR45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.cyto.2016.08.014","volume":"101","author":"H Mitoma","year":"2016","unstructured":"Mitoma H, et al. Molecular mechanisms of action of anti-TNF-alpha agents\u2014comparison among therapeutic TNF-alpha antagonists. Cytokine. 2016;101:56\u201363.","journal-title":"Cytokine."},{"issue":"9","key":"285_CR46","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261\u20135.","journal-title":"Clin Infect Dis"},{"key":"285_CR47","doi-asserted-by":"publisher","first-page":"i262","DOI":"10.1136\/bmj.i262","volume":"352","author":"P Raaschou","year":"2016","unstructured":"Raaschou P, et al. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016;352:i262.","journal-title":"BMJ."},{"issue":"9","key":"285_CR48","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886\u201395.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"285_CR49","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2515\/therapie\/2013037","volume":"68","author":"M Lapeyre-Mestre","year":"2013","unstructured":"Lapeyre-Mestre M, et al. Pharmacoepidemiology studies: what levels of evidence and how can they be reached? Therapie. 2013;68(4):241\u201352.","journal-title":"Therapie"},{"issue":"10","key":"285_CR50","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"RF Vollenhoven van","year":"2015","unstructured":"van Vollenhoven RF, et al. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol. 2015;42(10):1761\u20136.","journal-title":"J Rheumatol"},{"issue":"4","key":"285_CR51","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/cc11304","volume":"16","author":"PM Kasi","year":"2012","unstructured":"Kasi PM, et al. Clinical review: serious adverse events associated with the use of rituximab\u2014a critical care perspective. Critical Care. 2012;16(4):231.","journal-title":"Critical Care"},{"issue":"2","key":"285_CR52","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","volume":"22","author":"MJ Alomar","year":"2014","unstructured":"Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J. 2014;22(2):83\u201394.","journal-title":"Saudi Pharm J"},{"issue":"4","key":"285_CR53","doi-asserted-by":"publisher","first-page":"107327481772990","DOI":"10.1177\/1073274817729901","volume":"24","author":"C Bohra","year":"2017","unstructured":"Bohra C, Sokol L, Dalia S. Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control. 2017;24(4):1073274817729901.","journal-title":"Cancer Control"},{"issue":"6","key":"285_CR54","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"285_CR55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","volume":"37","author":"C Michel","year":"2017","unstructured":"Michel C, et al. Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig. 2017;37(5):415\u201322.","journal-title":"Clin Drug Investig."},{"issue":"6","key":"285_CR56","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/1756-185X.12659","volume":"19","author":"C Downey","year":"2016","unstructured":"Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: a literature review. Int J Rheum Dis. 2016;19(6):536\u201350.","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"285_CR57","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s10067-015-3026-7","volume":"34","author":"N Berghen","year":"2015","unstructured":"Berghen N, et al. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study. Clin Rheumatol. 2015;34(10):1687\u201395.","journal-title":"Clin Rheumatol"},{"key":"285_CR58","first-page":"241","volume":"2","author":"G Raval","year":"2010","unstructured":"Raval G, Mehta P. TNF-alpha inhibitors: are they carcinogenic? Drug Healthc Patient Saf. 2010;2:241\u20137.","journal-title":"Drug Healthc Patient Saf"},{"issue":"1","key":"285_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/art.30653","volume":"64","author":"DH Solomon","year":"2012","unstructured":"Solomon DH, Mercer E, Kavanaugh A. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results. Arthritis Rheum. 2012;64(1):21\u201332.","journal-title":"Arthritis Rheum"},{"key":"285_CR60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/DDDT.S41645","volume":"8","author":"CC Mok","year":"2013","unstructured":"Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Dev Ther. 2013;8:87\u2013100.","journal-title":"Drug Des Dev Ther"},{"key":"285_CR61","doi-asserted-by":"publisher","first-page":"561748","DOI":"10.1155\/2013\/561748","volume":"2013","author":"S Nakayama","year":"2013","unstructured":"Nakayama S. Autoimmune hepatitis triggered by anti-TNF-alpha therapy. Case Rep Med. 2013;2013:561748.","journal-title":"Case Rep Med"},{"issue":"24","key":"285_CR62","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.3748\/wjg.v21.i24.7584","volume":"21","author":"S Rodrigues","year":"2015","unstructured":"Rodrigues S, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. World J Gastroenterol. 2015;21(24):7584\u20138.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"285_CR63","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.anai.2015.06.004","volume":"115","author":"AA Mourad","year":"2015","unstructured":"Mourad AA, et al. Adverse reactions to infliximab and the outcome of desensitization. Ann Allergy Asthma Immunol. 2015;115(2):143\u20136.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"285_CR64","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/jcpt.12456","volume":"41","author":"T Flaig","year":"2016","unstructured":"Flaig T, et al. Tocilizumab-induced pancreatitis: case report and review of data from the FDA adverse event reporting system. J Clin Pharm Ther. 2016;41(6):718\u201321.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"285_CR65","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","volume":"76","author":"A Strangfeld","year":"2017","unstructured":"Strangfeld A, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Ann Rheum Dis. 2017;76(3):504\u201310.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"285_CR66","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.semarthrit.2013.09.005","volume":"43","author":"C Roubille","year":"2014","unstructured":"Roubille C, Haraoui B. Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review. Semin Arthritis Rheum. 2014;43(5):613\u201326.","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"285_CR67","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1517\/14740338.6.6.713","volume":"6","author":"IW Hammond","year":"2007","unstructured":"Hammond IW, et al. Database size and power to detect safety signals in pharmacovigilance. Expert Opin Drug Saf. 2007;6(6):713\u201321.","journal-title":"Expert Opin Drug Saf"},{"issue":"14","key":"285_CR68","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/sim.1157","volume":"21","author":"PG Heijden van der","year":"2002","unstructured":"van der Heijden PG, et al. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med. 2002;21(14):2027\u201344.","journal-title":"Stat Med"},{"issue":"2","key":"285_CR69","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1365-2125.2006.02746.x","volume":"63","author":"A Blenkinsopp","year":"2007","unstructured":"Blenkinsopp A, et al. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience. Br J Clin Pharmacol. 2007;63(2):148\u201356.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"285_CR70","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/pds.897","volume":"13","author":"K Grootheest van","year":"2004","unstructured":"van Grootheest K, et al. Pharmacists\u2019 role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004;13(7):457\u201364.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"285_CR71","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2147\/IPRP.S105881","volume":"6","author":"MA Hadi","year":"2017","unstructured":"Hadi MA, et al. Pharmacovigilance: pharmacists\u2019 perspective on spontaneous adverse drug reaction reporting. Integr Pharm Res Pract. 2017;6:91\u20138.","journal-title":"Integr Pharm Res Pract"},{"issue":"6","key":"285_CR72","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/014107689108400612","volume":"84","author":"AP Fletcher","year":"1991","unstructured":"Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991;84(6):341\u20134.","journal-title":"J R Soc Med"},{"issue":"5","key":"285_CR73","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29(5):385\u201396.","journal-title":"Drug Saf"},{"issue":"3","key":"285_CR74","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1046\/j.1365-2125.1999.00881.x","volume":"47","author":"C Pierfitte","year":"1999","unstructured":"Pierfitte C, et al. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol. 1999;47(3):329\u201331.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"285_CR75","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1592\/phco.24.8.743.36068","volume":"24","author":"NR Hartnell","year":"2004","unstructured":"Hartnell NR, Wilson JP. Replication of the Weber effect using postmarketing adverse event reports voluntarily submitted to the United States Food and Drug Administration. Pharmacotherapy. 2004;24(6):743\u20139.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"285_CR76","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman KB, et al. The Weber effect and the United States Food and Drug Administration\u2019s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283\u201394.","journal-title":"Drug Saf"},{"issue":"10","key":"285_CR77","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","volume":"30","author":"A Pariente","year":"2007","unstructured":"Pariente A, et al. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. Drug Saf. 2007;30(10):891\u20138.","journal-title":"Drug Saf"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-018-0285-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0285-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0285-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T19:04:19Z","timestamp":1559675059000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-018-0285-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,5]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s40259-018-0285-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,5]]},"assertion":[{"value":"5 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No funding was received in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ariane G. S. Araujo, Helena H. L. Borba, Fernanda S. Tonin, Luana Lenzi, Rafael Venson, Roberto Pontarolo, and Astrid Wiens have no conflicts of interest directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was not required for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}